The NASA Reduced Gravity Office (RGO) uses scopolamine (SCOP) alone and in combination with dextoamphetamine (DEX) to treat motion sickness symptoms during DC-9 parabolic flights. The medications are sometimes dispensed as custom dosage forms in gelatin capsules for convenience. Reports of treatment failure during flights by the flight surgeons suggest that these formulations may be less efficacious for the treatment of motion sickness due to unreliable and inadequate bioavailability. We estimated bioavailability of four different oral formulations used by the NASA RGO physicians for the treatment of motion sickness.

Download full-text PDF

Source

Publication Analysis

Top Keywords

motion sickness
12
dosage forms
8
treatment motion
8
relative bioavailability
4
bioavailability scopolamine
4
scopolamine dosage
4
forms interaction
4
interaction dextroamphetamine
4
dextroamphetamine nasa
4
nasa reduced
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!